Gaithersburg, MD, November 2, 2015 – MaxCyte® Inc., the pioneer in cell therapies using scalable, high-performance cell transfection systems, announces that data generated using its flow electroporation platform will be presented at the PEGS Europe. There will be three podium presentations of MaxCyte data.
The three presentations are:
Construction and Use of Large Antibody Libraries in Mammalian Cells
Presented By: Dr. John McAfferty, CEO, IONTAS Ltd.
Session Info: Antibody Engineering Stream: Display of Antibodies-Eukaryotic Display
Presentation Time: Monday November 2, 2015, 5:05 pm
Efficient Mammalian Cell Transfection for Antibody Discovery
Presented By: Michael R. Dyson, Chief Technology Officer, IONTAS Ltd
Session Info: Antibody Engineering Stream: Empowering Novel Biologics-Using Display for Immunotherapy Applications
Presentation Time: Tuesday November 3, 2015, 12:35 pm
Scaling Up or Scaling Down Flow Electroporation for Streamlined Production Biotherapeutic Products
Presented By: Professor Dr. Matthias Peipp, Christian-Albrechts-University and Dr. Peer Heine, MaxCyte Inc.
Session Info: Protein Expression Stream: Applying Expression Platforms-Cell Line Development
Presentation Time: Wednesday November 4, 2015, 12:30 pm
About MaxCyte
MaxCyte is the leader in driving the next generation of cell-based medicines. MaxCyte’s cell modification technology, flow electroporation, is used for discovery, development, and manufacture of small molecule, biologic, and cell-based therapeutics. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of transfected cells for a broad array of applications.
For more information, http://www.maxcyte.com.
Help employers find you! Check out all the jobs and post your resume.
